SEC Form 4 · accession 0001479290-19-000020
Revance Therapeutics, Inc. · RVNC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
L Daniel Browne
Officer — CEO and President · Director
Period of report
Feb 15, 2019
Accepted (ET)
Feb 20, 2019 · 9:31 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479290
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 15, 2019 | F | 3,154 | $17.69 | D | 174,389 | D | |
| Common Stock | Feb 19, 2019 | S | 5,446 | $17.68 | D | 168,943 | D | |
| Common StockF3 | holding | — | — | — | 409 | I | See footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents the number of shares withheld by and surrendered to the issuer on February 15, 2019, to satisfy tax withholding obligations that arose in connection with the vesting of a 2017 Restricted Stock Award (the "RSA") for 25,800 shares. The RSA vests in three equal annual installments from February 15, 2017, subject to Mr. Browne's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date.
- F2The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Mr. Browne.
- F3These shares are held by the Dan and Brenda Browne Living Trust. Mr. Browne is a Trustee of the Dan and Brenda Browne Living Trust.